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Purpose: Patient adherence to antidepressants is poor. However, this is rather unsurprising, 
given the equivocal efficacy, side effects, and practical problems of antidepressants. The aim 
of this study was to examine a wide array of patient experiences and perceptions regarding the 
efficacy, side effects, and practical problems of antidepressants, as well as their associations with 
nonadherence, and whether patients’ perceived self-efficacy moderated these associations.
Patients and methods: Experiences and perceptions of 225 patients, recruited through 
 community pharmacies, were efficiently assessed with the Tailored Medicine Inventory. 
 Nonadherence was assessed through self-report and pharmacy refill data.
Results: Many patients were not convinced of the efficacy, thought the efficacy to be limited or 
did not believe antidepressants to prevent relapse, were worried about or had experienced one 
or more side effects, and/or had experienced one or more practical problems regarding informa-
tion, intake, and packaging. Being convinced of efficacy was associated with lower intentional 
 nonadherence (odds ratio [OR] 0.9, 95% confidence interval [CI] 0.8–0.96). A higher number 
of practical problems experienced was associated with increased unintentional  nonadherence 
(OR 1.3, 95% CI 1.1–1.7). Higher perceived self-efficacy regarding taking  antidepressants 
was  associated with lower unintentional nonadherence (OR 0.7, 95% CI 0.5–0.9). Perceived 
self-efficacy did not moderate associations of patient experiences and perceptions with 
nonadherence.
Conclusion: Assessing a wide array of patients’ experiences and perceptions regarding the 
efficacy, side effects, and practical problems of antidepressants contributes to better understand-
ing of nonadherence to antidepressants. Guiding physician–patient conversations by patients’ 
experiences and perceptions may reduce both unintentional and intentional nonadherence. 
Also, it may give rise to considerations of prudent discontinuation, eg, when patients are not 
convinced of the efficacy.
Keywords: antidepressants, efficacy, side effects, practical problems, patients’ experiences 
and perceptions, perceived self-efficacy, nonadherence
Introduction
There is ongoing debate about treatment with antidepressants. Two meta-analyses 
found antidepressants to reduce symptoms effectively1 and to prevent relapse,2 
whereas another meta-analysis refuted their efficacy, except for treatment of severe 
depression.3 Findings from yet another study suggested that the reported successful 
prevention of relapse was caused by a methodological artifact.4 Furthermore, antide-
pressants frequently cause side effects,5 which could make the medicine worse than 
the ailment, especially so when the presence of side effects is paired with an absence 
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In the US, approximately 10% of individuals aged 12 years 
and older were treated with antidepressants in 2005–2008.6 
In the Netherlands, which was the setting of our study, as 
many as 956,270 people (or ∼6% of the total population) 
were prescribed antidepressants in 2012.7
In view of the ambiguous findings concerning the efficacy 
and the reported side effects of antidepressants, the high preva-
lence of patients treated with antidepressants could at least 
in part reflect overprescribing. Indeed, an estimated 11% of 
patients who are treated with antidepressants in primary care do 
not fulfill diagnostic criteria for depressive or anxiety disorder.8 
Overprescribing may also explain the substantial nonadherence 
rates reported in the literature.9,10 Therefore, understanding 
antidepressant use from the perspective of patients is of crucial 
importance. However, previous studies did not examine a wide 
array of patient experiences and perceptions with regard to 
antidepressant use. We therefore adopted a framework using 
a sensible taxonomy of experiences and perceptions regard-
ing the efficacy and side effects of antidepressants as well as 
practical problems associated with their use.
We extended previous examinations5,9,11–13 in five ways. 
First, although previously studied patient experiences and 
perceptions with regard to the efficacy of antidepressants 
varied from perceived necessity11 and confidence of the 
efficacy12 to perceived symptom relief,13 a comprehensive 
assessment of patient experiences and perceptions regard-
ing the efficacy of antidepressants seems to be lacking. We 
therefore examined experiences and perceptions with regard 
to the efficacy of antidepressants in a comprehensive manner. 
Second, because known side effects were mostly addressed 
in the literature, we also addressed other side effects experi-
enced or considered relevant by patients. Third, we examined 
practical problems of using antidepressants. Fourth, although 
many studies examined the occurrence of side effects, wor-
ries and burden caused by side effects have seldom been 
addressed. Fifth, in studying associations of nonadherence 
with patients’ experiences and perceptions of antidepressants, 
we distinguished between intentional or conscious nonadher-
ence versus unintentional nonadherence due to forgetting. 
We did so because it makes sense that unintentional and 
intentional nonadherence are likely to be associated with 
different experiences and perceptions. Such differential 
relationships have received little attention so far.
A concern, however, regarding extensive assessment of 
patients’ experiences and perceptions is questionnaire burden. 
We therefore developed the Tailored Medicine Inventory 
(TMI). The TMI efficiently assesses medicine- related 
 experiences and perceptions regarding side effects and 
practical problems through logical routes that allow skipping 
of irrelevant perceptions and experiences, thereby keeping 
questionnaire burden at a minimum level (see the Materials 
and methods section).
In addition to antidepressant-associated experiences and 
perceptions, we studied patients’ perceived self-efficacy with 
regard to prolonged antidepressant use. Self-efficacy refers 
to patients’ own perceptions of their ability to accomplish 
a particular behavior.14 Previously, higher perceived self-
efficacy was shown to be associated with better medicine 
taking and less nonadherence.15
Accordingly, the objectives of this study were to assess 
a wide array of patients’ experiences and perceptions with 
regard to using antidepressants, to examine which of these 
were associated with intentional and unintentional non-




Patients were recruited through community pharmacies. 
They were invited to participate if in the previous year 
tricyclic antidepressants, selective serotonin reuptake 
inhibitors, or other antidepressants, including serotonin–
norepinephrine reuptake inhibitors and tetracyclic antide-
pressants, had been dispensed to them. For ethical reasons, 
patients were not approached in cases of psychotic disorders 
or dementia, severe or terminal illness, or for other reasons 
judged to be relevant by their pharmacist, eg, psychosocial 
problems. Patients participated through filling out an online 
 questionnaire. For all patients, refill data were extracted 
from the automated dispensing records of the pharmacy. 
To reduce selection bias or participation by predominantly 
adherent patients with access to the Internet, interviews 
were conducted in the pharmacy with older patients and with 
patients who were suspected to be nonadherent. Patients 
were suspected to be nonadherent if their refill histories 
revealed that they had missed one or more  prescriptions. 
Clinical characteristics included status of use (being a 
starter or recent user versus (vs) a user or a stopper), dura-
tion and indication of treatment, having ever been admitted 
to a psychiatric hospital or ward, and additional treatment 
with psychotherapy. The medical ethical committee of the 
Leiden University Medical Center approved the study. All 
patients gave informed consent on an electronic form prior 
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Antidepressants in primary care
The Tailored Medicine inventory
As part of this study, we developed the TMI to assess 
patients’ experiences and perceptions regarding the effi-
cacy, side effects, and practical problems of antidepres-
sants. These experiences and perceptions were identified 
through literature about nonadherence to medicines in 
general and to anti depressants in particular (literature refer-
ences are reported in each appropriate section discussing 
perceptions and experiences regarding the efficacy, side 
effects, and practical problems). To evaluate potential 
paucities in the literature, we also reviewed qualitative 
data from face-to-face focus groups of a previous study 
that was conducted with primary care patients who were 
treated with antidepressants, reports made by patients on a 
website maintained by the Dutch Institute of Rational Med-
icine Use,16 and through information from the Summary 
of Product Characteristics,17 an authorization document 
for medicines of the European Medicines Agency. Four 
pharmacists and a psychiatrist reviewed the content of the 
items. The items were written at a difficulty level requiring 
8–9 years of formal education using the Flesch–Kincaid 
formula.18 Experiences and perceptions with regard to side 
effects and practical problems were efficiently assessed by 
means of logical routes (Figure 1). These routes enabled us 
to assess experiences and perceptions in a manner that was 
comprehensive but also efficient. To avoid order effects, 
items and item categories were presented in random order 
wherever appropriate. A pilot study was conducted among 
nine volunteers and eleven patients to assess item content, 
upon which we concluded that only minor rewording of 
items was necessary.
TMi: experiences and perceptions with 
regard to the efficacy of antidepressants
Experiences and perceptions with regard to the efficacy 
of antidepressants were assessed with regard to relapse 
prevention, being convinced of the efficacy and perceived 
necessity, education about efficacy, as well as symptomatic 
efficacy11,12,16,19–22 (see Table S1).
Responses to each statement were scored on 5-point 
scales (0, fully disagree; 4, fully agree). Consistent with the 
categories of experiences and perceptions, factor analysis 
(varimax rotation) revealed four dimensions: being convinced 
of the efficacy (five items), education about efficacy (three 
items), relapse prevention (four items), and symptomatic 
efficacy (four items). As the internal consistencies were 
insufficient for the dimensions of education about efficacy 
(α=0.69) and relapse prevention (α=0.62), these dimen-
sions were not further studied. The dimension of being 
convinced of the efficacy had high internal consistency 
after removal of one item (α=0.84, scoring range 0–16) and 
the symptomatic efficacy dimension had sufficient internal 























1. Assessment of classes of side effects
2. Assessment of specific side effects eg Sexual problems
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TMI: worries about and experiences  
with side effects of antidepressants
Worries about side effects were assessed for known side 
effects of antidepressants that included dizziness, gas-
trointestinal complaints, dry mouth, sweating, emotional 
flatness, insomnia, drowsiness, tiredness, decreased 
libido, and for male patients also problems with erection 
and ejaculation.5,13,17 Experiences with these known side 
effects and less well-known side effects of antidepressants 
were assessed with a comprehensive checklist consisting 
of side effects with regard to memory and concentration, 
gynecologic complaints (in women), restlessness, skin and 
hair problems, heart or bladder problems, gastrointestinal 
problems, and muscle and joint complaints.5,13,17,23,24 To 
avoid test burden, experiences with regard to side effects 
were efficiently assessed in a three-step manner enabled 
by logical routes (see Figure 1 for an illustration). First, 
we presented the classes of side effects. Patients had to 
indicate which class or classes of side effects they had 
experienced. To avoid reporting bias, the specific side 
effects belonging to a class were displayed in parentheses 
behind that class. Subsequently, for each endorsed class 
of side effects, patients had to indicate which specific side 
effect or side effects they had experienced. Finally, for the 
side effect or side effects that a patient had experienced, 
he or she had to indicate the level of bother. Worries about 
side effects were also efficiently assessed but in a two-step 
manner adopting only steps 2 and 3 of the approach shown 
in Figure 1. Levels of bother and worry were assessed on 
a 5-point scale (1, not bothersome/worrying at all; 5, very 
bothersome/worrying).
TMi: experiences with regard to practical 
aspects of antidepressant use
Practical problems of antidepressant use were also assessed 
in a tailored manner analogous to the assessment of expe-
rience of side effects. The comprehensive checklist of 
practical problems consisted of specific problems with 
regard to written information,15,25 logistical problems such 
as availability and getting refills,24 dosage and intake,24–26 
packaging,25 and other problems.27 Here too, level of bother 
was assessed on a 5-point scale (1, not bothersome at all; 5, 
very bothersome).
Perceived self-efficacy
Perceived self-efficacy with regard to medicine taking and 
learning about medication was assessed with the eight-item 
Medication Understanding and Use Self-Efficacy Scale 
(MUSE) scale.15 Internal consistencies (α) were 0.84 for 
perceived self-efficacy with regard to taking medication (four 
items, scoring range 0–12), and 0.83 with regard to learning 
about medication (four items, scoring range 0–12).
Therapy nonadherence
Self-reported nonadherence to antidepressants was assessed 
with items from the Medication Adherence Rating Scale 
(MARS-5).28 Because the MARS-5 seemed to measure 
predominantly intentional nonadherence and unintentional 
nonadherence seemed to be underrepresented, assessment 
of nonadherence was complemented with the new Morisky 
Medication Adherence Scale (MMAS-8),29 and additional 
questions about forgetting to take antidepressants and 
 persistence. As we were interested in unintentional and inten-
tional nonadherence as underlying dimensions, we did not 
calculate total scores on the instruments. Rather, we pooled 
both instruments and the additional questions, and subjected 
the data to factor analysis. Factor analysis (varimax rotation) 
and internal consistency measures indeed confirmed that the 
items measured unintentional nonadherence due to forgetful-
ness and intentional or deliberate nonadherence as underlying 
dimensions. Accordingly, for every patient, an unintentional 
nonadherence total score was calculated by summing the items 
measuring unintentional nonadherence and an intentional 
nonadherence total score by summing the items measuring 
intentional nonadherence (Table S2). In addition, overall 
nonadherence was inferred from the pharmacy refill data. To 
that end, a Medication Possession Ratio (MPR) was calculated 
using information on antidepressant dispensing data prior to 
the date on which patients were recruited for the study. We 
followed the methodology previously described and tested 
by Gardarsdottir et al.30 So-called treatment episodes were 
calculated by allowing 90-day gaps or the duration of a stan-
dard prescription in the Netherlands between the theoretical 
end date of an antidepressant prescription and a successive 
antidepressant prescription. Where the dispensing date of the 
successive antidepressant prescription preceded the theoretical 
end date of the prior prescription, this overlap was accounted 
for. The MPR was calculated for the last treatment episode of 
each patient prior to recruitment.
statistical analysis
Because the total scores of unintentional and intentional 
nonadherence were skewed, these were dichotomized 
at ,80% vs $80% of the score distribution (unintentional 
 nonadherence, score of #2 vs $3; intentional nonadher-
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Antidepressants in primary care
and unintentional nonadherence and the following variables 
were first examined in a series of univariate logistic regres-
sion analyses: demographic and clinical characteristics, the 
extent to which patients were convinced of the efficacy and 
perceived symptomatic efficacy, the number of side effects 
patients were worried about and that they had experienced, 
the number of experienced practical problems, and perceived 
self-efficacy. Variables that had a univariate association with 
nonadherence (P,0.10) were subsequently entered into mul-
tivariate regression models as independent variables. For each 
significant independent variable, we subsequently included 
an interaction term between that variable and perceived 
self-efficacy with regard to taking and/or learning about 
antidepressants. Subsequently, these analyses were repeated 
with the MPR calculated from the pharmacy refill data (MPR) 
as the dependent variable (adherent $80% vs nonadherent 
,80%). All analyses were done with SPSS software (IBM 
Corporation, Armonk, NY, USA).
Results
Table 1 presents the demographic and clinical charac-
teristics of the 225 men and women who participated. 
Ample variation was observed for most demographic and 
clinical  characteristics. About two-thirds of the patients 
were treated with antidepressants for $4 years, over 
half were treated with a selective serotonin reuptake 
inhibitor, and over a third were treated with additional 
psychotherapy.
experiences and perceptions with regard 
to the efficacy of antidepressants
Negative or neutral experiences and perceptions (disagree and 
neutral vs agree) with regard to the efficacy of antidepressants 
were reported by many patients (see Table 2). Over 10% of 
patients doubted the efficacy, a third were not convinced of 
the efficacy, did not believe the use of antidepressants to be 
necessary, or thought the efficacy to be limited, four of ten 




Women, n (%) 149 (66)
Mean age, years (sD) 51.1 (13.5)
Married or living together, n (%) 176 (78)
higher educated (vs low to medium), n (%) 57 (25)
Clinical characteristics
status of use, n (%)
 starters and recent users ,3 months 18 (8)
 Users .3 months 183 (81)
 stoppers 24 (11)
Duration of use (only users .3 months), n (%)
 0–1 years 26 (14)
 1–4 years 37 (20)
 4 years or longer 120 (66)
Type of antidepressant, n (%)
 TcA 38 (17)
 ssri 137 (61)
 Othera 50 (22)
indication for use, n (%)
 Depression 134 (60)
 Anxiety or panic 103 (46)
 Otherwise 82 (36)
Ever been admitted to psychiatric hospital/ward, n (%) 14 (6)
Additional treatment with psychotherapy, n (%) 84 (37)
Note: aIncludes serotonin–norepinephrine reuptake inhibitors and tetracyclic 
antidepressants.
Abbreviations: sD, standard deviation; TcA, tricyclic antidepressants; ssri, 
selective serotonin reuptake inhibitor; vs, versus.





n % n %
 1.  The use of antidepressants  
is necessary for me
64 28 161 72
 2.  I am convinced of the efficacy  
of antidepressants
73 32 152 68
 3.  I have doubts about the efficacy  
of antidepressants
193 86 32 14
 4.  Antidepressants have a limited  
efficacy
152 68 73 32
 5.  i expect antidepressants to help 68 30 157 70
 6.  i know how antidepressants work 80 36 145 64
 7.  I received information about  
how antidepressants work
65 29 160 71
 8.  i know why i have to use  
antidepressants
25 11 200 89
 9.  i am using antidepressants,  
because I was afraid my  
complaints would come back
102 45 122 55
10.  Antidepressants prevent my  
complaints from coming back
92 41 133 59
11.  Using antidepressants resolves  
your problems
151 67 74 33
12.  The longer you use antidepressants,  
the better they work
164 73 61 27
13.  It took a long time, before my  
antidepressants worked
154 69 70 31
14.  Owing to antidepressants,  
i have more energy
140 62 84 37
15.  Owing to antidepressants,  
I sleep better
128 57 96 43
16.  Because of my antidepressants,  
I feel physically better
109 48 115 51
17.  Because of my antidepressants,  
I feel mentally better
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patients did not believe antidepressants to prevent relapse, 
and a third did not expect antidepressants to help. One in ten 
patients did not know why they had to use antidepressants, 
a third had not received information about the efficacy and/
or did not know how antidepressants worked. A quarter of 
the patients did not feel mentally better, half did not feel 
physically better, nearly two-thirds did not get more energy, 
and more than half did not sleep better, whereas two-thirds 
did not believe antidepressants to resolve their problems and 
a third thought it took a long time before antidepressants 
worked. The mean total scores on the dimensions of being 
convinced of efficacy and symptomatic efficacy were 11.7 
(standard deviation [SD] 3.7, observed range 0–16) and 7.3 
(SD 3.1, observed range 0–12) respectively.
Worries about and experiences  
with side effects of antidepressants
Patients were worried on average about three side effects 
(SD 2) and had experienced on average four side effects 
(SD 4). Table 3 presents the known side effects of antidepres-
sants (both worry and experience assessed) and less-known 
and other side effects (only experience assessed).
Table 3 Worries about and experiences of side effects of antidepressants
Side effects Worry about side effects Experiences of side effects
Yes,  
n (%)




M level of  
bother (SD)a
Side effects associated with antidepressants
Dizziness 40 (18) 2.8 (1.2) 16 (7) 4.1 (1.1)
Vomiting/feeling nauseous 9 (4) 2.6 (1.3) 6 (3) 4.2 (1.0)
gastrointestinal complaints 37 (16) 2.6 (1.4) 23 (10) 4.6 (0.8)
Dry mouth 53 (24) 2.3 (1.3) 50 (22) 3.7 (1.2)
sweating 55 (24) 2.7 (1.2) 42 (19) 4.4 (0.7)
Emotional flatness 54 (24) 3.1 (1.2) 42 (19) 4.1 (1.1)
insomnia 23 (10) 3.3 (1.2) 29 (13) 4.5 (0.8)
Drowsiness 50 (22) 3.5 (1.2) 36 (16) 4.1 (1.0)
Tiredness 68 (30) 3.3 (1.3) 52 (23) 4.3 (0.9)
Libido decrease 95 (42) 3.4 (1.3) 84 (37) 4.2 (1.1)
Decreased erection or ejaculation 33 (15) 3.5 (1.1) 28 (12) 3.3 (1.1)
Other side effects
Memory, concentration or tiredness
 Forgetfulness 42 (19) 4.4 (0.8)
 Diminished concentration 37 (16) 4.4 (0.6)
gynecological complaints
 Painful or sensitive breasts 8 (4) 3.8 (1.0)
 Vaginal discharge, vaginal dryness, or vaginal itch 11 (5) 3.9 (1.0)
 Hot flushes 18 (8) 4.1 (0.9)
 Vaginal blood loss 1 (0.4) 5 (nA)
emotional
 Feeling restless 33 (15) 4.6 (0.6)
skin or hair
 hair loss 15 (7) 4.0 (0.9)
 rash 12 (5) 4.5 (0.5)
Heart, vessels, or bladder
 heart palpitations 16 (7) 4.3 (0.9)
 edema 16 (7) 4.4 (0.8)
 Urinary retention 8 (4) 3.8 (1.6)
 incontinence 14 (6) 4.5 (0.9)
Gastrointestinal problems
 Stomach ache, stomach cramps, heartburn, or bloating 28 (12) 4.4 (0.6)
Muscles, bones, or joints
 Ache, stiffness, swelling, or inflammation of joints 34 (15) 4.4 (0.7)
 Trembling 17 (8) 4.2 (0.9)
 Backache 23 (10) 4.5 (0.7)
 Muscular pain or muscle cramps 33 (15) 4.4 (0.8)
Note: aAssessed on a scale ranging from 1 to 5.
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Antidepressants in primary care
Table 4 Experiences of practical problems of antidepressant use
Practical problems Yes,  
n (%)
M level of 
bother (SD)g
information,a intake of tablets,b  
and packaging and blisterc
62 (28) 3.5 (0.9)
Logistical problemsd 47 (21) 3.6 (1.0)
limitations in daily lifee 46 (20) 2.9 (0.9)
Medication interactionf 50 (22) 3.0 (1.1)
Notes: acontradictory, redundant, small font size, text comprehension; btablets – 
how to take, number of tablets in blister impractical, needed to be broken for correct 
dose, were difficult to break or to swallow, taste, took a long time to get correct 
dose, use difficult to fit into daily routine, dose skipping; cunclear label, difficulties 
regarding opening package, pressing tablets out of blister or cutting part of blister, 
changes of package, medicine name change, tablet color/form; dantidepressants 
unavailable or unclear how to get refills, getting insufficient antidepressant tablets, 
having to go too often to pharmacist or physician; ewhether antidepressant use 
permitted alcohol consumption and affected driving ability negatively; fmedicine 
interactions; gassessed on a scale ranging from 1 to 5.
Abbreviation: sD, standard deviation; M, mean.
Worry about side effects
Many patients expressed worry about libido decrease, tiredness, 
emotional flatness, sweating, and a dry mouth (see Table 3). 
Mean levels of worry were on average moderate to high, vary-
ing between patients but equal for most side effects.
experience of side effects
Most frequently experienced known side effects of anti-
depressants were libido decrease, tiredness, feeling drowsy, 
insomnia, emotional flatness, sweating, a dry mouth, gastroin-
testinal complaints, and decreased erection or ejaculation (see 
Table 3). Other side effects that were also often experienced 
were forgetfulness, diminished concentration, feeling restless, 
and musculoskeletal complaints. Fewer patients experienced 
side effects, such as incontinence, urinary retention, edema, rash, 
hair loss, vaginal discharge, dryness, or itch, and painful breasts. 
Most side effects posed substantial bother to the patients, but 
there was also individual variation in the level of bother.
Experience of practical problems  
of antidepressant use
A total of 115 patients (52%) had experienced one or more 
practical problems. The most frequently experienced practi-
cal problems concerned information of leaflets, intake of 
tablets, and packaging. Together with logistical problems 
(eg, refill problems), these posed the greatest levels of bother 
(see Table 4).
Therapy nonadherence
Increasing age was associated with a lower likelihood of unin-
tentional nonadherence. A higher number of practical problems 
experienced was associated with an increased likelihood of 
Table 5 Multivariate logistic regression results: associations 
of unintentional and intentional nonadherence with patients’ 
experiences and perceptions with regard to antidepressant use
Predictors Nonadherence
Unintentional Intentional MPR
Odds ratio  
(95% CI)
Odds ratio  
(95% CI)








  Married/living 
together
1.2 (0.4–4.2)




Convinced of  
efficacy score
0.9 (0.8–0.96)†
Number of  




 no reference reference
 Yes 1.4 (0.5–4.2) 1.8 (0.9–4.0)












Abbreviations: MPR, medication possession ratio; CI, confidence interval; MUSE, 
Medication Understanding and Use Self-Efficacy Scale.
unintentional nonadherence. Being convinced of the efficacy 
was associated with lower intentional nonadherence. Increased 
perceived self-efficacy with regard to taking antidepressants 
was associated with lower unintentional  nonadherence. Because 
perceived self-efficacy was not associated with intentional 
nonadherence, analysis of moderating influence of perceived 
self-efficacy was restricted to unintentional  nonadherence. No 
moderating effects of perceived self-efficacy on associations 
between experiences and perceptions with regard to antidepres-
sants and unintentional nonadherence were found (data not 
shown). Turning to nonadherence as assessed with the MPR 
calculated from the refill data, it was shown that only longer 
duration of treatment with antidepressants was associated with 
increased nonadherence (see Table 5).
Discussion
Our findings demonstrate that a substantial number of 
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about or had experienced side effects, particularly decreased 
libido, tiredness, feeling drowsy, insomnia, emotional flat-
ness, sweating, a dry mouth, and intestinal complaints. 
These side effects were consistent with those reported in 
the  literature.13,16 Furthermore, the high levels of evoked 
worry and bother suggest that most side effects imposed a 
nonnegligible burden. At the same time, there was consider-
able individual variation in these levels of evoked worry and 
bother. In addition, roughly half the patients had experienced 
one or more problems of a practical nature.
That being convinced of the efficacy was associated with 
lower intentional nonadherence seems obvious. However, 
a less obvious result was that worry about or experience of 
side effects was not associated with nonadherence. Previous 
findings regarding prediction of nonadherence by experi-
ence of side effects were contradictory.5,12 Perhaps only 
side effects that are substantially bothering are predictive of 
 nonadherence. Furthermore, practical problems were found 
to increase the likelihood of unintentional  nonadherence. 
Consistent with findings by Cameron et al,15 perceived 
self-efficacy was predictive of nonadherence; in our case, 
unintentional nonadherence. However, perceived self-
efficacy did not moderate associations of nonadherence with 
experiences and perceptions. Therefore, higher perceived 
self-efficacy seems to promote adherence regardless of 
whether antidepressant-related experiences and perceptions 
were favorable or unfavorable. The finding that a decrease of 
unintentional nonadherence was associated with increasing 
age was consistent with a previous finding.22 That experi-
ences and perceptions were not predictive of nonadherence 
as assessed with the MPR calculated from the pharmacy refill 
data was an unexpected finding at first sight. Yet on closer 
inspection, a plausible explanation for this finding could 
be that the MPR reflects both unintentional and intentional 
nonadherence, whereas different experiences and perceptions 
were shown to be differentially related to unintentional and 
intentional nonadherence.
Understanding patients’ experiences and perceptions with 
regard to antidepressant use is important, as it could serve a 
dual purpose. First, it is likely to decrease patients’ failure to 
adhere to treatment with antidepressants. For patients who 
wish to continue treatment, better coping with resolving 
practical barriers and boosting perceived self-efficacy are 
likely to decrease nonadherence. Second, it might actually 
prevent overprescribing of antidepressants. Overprescrib-
ing of antidepressants is plausible. Meta-analytic findings 
regarding the efficacy of antidepressants were equivocal,1–3 
antidepressants are known to cause multiple side effects,5 the 
rates of  nonadherence reported in the literature are high,9,10 
and a recent study found that as many as 11% of primary care 
patients who are treated with antidepressants do not fulfill 
criteria for depressive or anxiety disorder.8 Knowing patients’ 
perceptions and experiences with regard to antidepressants 
could therefore offer possible explanations for patients’ 
refusal of an overprescribed medicine, although it should 
be noted that we did not find experience of side effects to be 
associated with nonadherence. Therefore, for patients with 
mild depression who are not convinced of the efficacy of anti-
depressants, prudent discontinuation should be contemplated 
too. Such a patient-centered approach would be an interesting 
future avenue for clinical practice and research.
Our findings have other implications for clinicians too. 
First, our findings revealed that most side effects impose 
a moderate-to-high burden and that less well-known side 
effects of antidepressants were experienced too. This indi-
cates the need to look broadly at a wide array of side effects. 
Second, the finding that the levels of evoked worry and bother 
varied substantially among individual patients indicates 
the need to complement assessments of mere occurrence 
of side effects with the level of worry and bother evoked 
by these side effects, both in study settings and in clinical 
practice. Third, although practical problems have received 
less attention in the literature, the fact that experiencing 
practical problems was associated with an increased likeli-
hood of unintentional nonadherence underlines the need 
for physicians and pharmacists to closely monitor these in 
addition to side effects.
There were various strengths to assessing experiences and 
perceptions using the TMI. First, development of the TMI 
was based on thorough review of the literature and findings 
from focus groups. Second, with regard to side effects, we 
not only addressed experiences but also worry about side 
effects. Third, our efficient administration of the question-
naire, ie, skipping irrelevant items, is new in this field. For 
clinicians and researchers, the obvious advantage is that our 
instrument enables assessment of a wide array of experiences 
and perceptions simultaneously. This reduces the chance of 
overlooking crucial ones and diminishes confounding in the 
analysis. At the same time, questionnaire burden is probably 
prevented. Because there seems not to be a single cause of 
nonadherence,31 and different perceptions or negative expe-
riences may explain nonadherence for different patients, 
assessing a wide array of experiences and perceptions is 
likely to be unavoidable. The TMI or similar methodologies 
therefore deserve adoption in future research. Consistent with 
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may explain nonadherence for different patients is the finding 
from a systematic review showing no consistent indications 
for which interventions may be effective.9 It is therefore 
more likely that individually tailored interventions targeting 
the specific problems of a patient are more efficacious. In 
this regard, we would recommend employment of the TMI 
as a boon to get insight into patients’ misperceptions and 
specific problems as an impetus for such individually tailored 
adherence-improving interventions. Besides nonadherence, 
another instance where input from the TMI could be valu-
able are decisions to switch to another antidepressant. Other 
strengths of the study were that there was ample variation in 
patients’ demographic and clinical characteristics, and that 
the major types of antidepressants were studied.
There were also limitations. Clinical characteristics were 
assessed by self-report and such characteristics as comorbid 
medical conditions, personality disorders, and other Axis II 
disorders and substance abuse could not be assessed. Fur-
thermore, we did not study interpersonal factors, such as 
the patient–physician relationship, degree of involvement 
in treatment decisions, physician attitudes toward antide-
pressants, and such disease factors as severity of the dis-
ease, social stigma, and patient’s beliefs about the disease. 
However, this was done to focus our study on experiences 
and perceptions directly related to medicine use. Moreover, 
studying both medicine-related perceptions and interpersonal 
factors in one questionnaire was likely to confound interper-
sonal and disease factors with medicine-specific perceptions 
and experiences.
Assessment of nonadherence has potential  shortcomings. 
Self-reported intentional nonadherence is liable to social 
desirability bias and perhaps self-serving bias too. Self-
reported unintentional nonadherence is necessarily limited to 
the instances of forgetting that were afterwards remembered 
by participants. On the other hand, limitations of inferring 
nonadherence from pharmacy refill data are that this does 
not permit distinction between unintentional and intentional 
nonadherence and that it does not guarantee that patients 
actually take their antidepressants. This is why we inferred 
nonadherence from both self-report and refill data. Fur-
thermore, selection bias may have occurred. In this regard 
though, the ample variance in relevant demographic and 
clinical background variables of our sample was reassur-
ing. Finally, a limitation with respect to study design was 
that the study was cross-sectional rather than longitudinal. 
As a result, we could not study changes in experiences 
and perceptions as well as incident nonadherence and 
discontinuation.
Conclusion
Taken together, insight into a wide array of patients’ expe-
riences and perceptions with regard to antidepressants is 
likely to contribute to better understanding of antidepressants 
from the perspective of patients. This is likely to improve 
 nonadherence. At the same time, discontinuation of anti-
depressants should be contemplated for patients with mild 
complaints who are not convinced of their efficacy.
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Table S1 Items to assess experiences and perceptions with regard to the efficacy of antidepressants
Items, and their factor loadings Factor dimensions
All items scored on 5-point scales: 0, fully disagree; 4, fully agree Ia IIb IIIc IVd
 1.  The use of antidepressants is necessary for me 0.66 0.38 0.21 0.12
 2.  I am convinced of the efficacy of antidepressants 0.72 0.33 0.21 0.16
 3.  I have doubts about the efficacy of antidepressants† 0.82 0.02 0.03 0.19
 4.  Antidepressants have a limited efficacy†,** 0.45 -0.35 0.15 0.15
 5.  i expect antidepressants to help 0.64 0.36 0.15 0.19
 6.  i know how antidepressants work 0.13 0.76 0.12 0.13
 7.  I received information about how antidepressants work 0.18 0.67 0.06 0.12
 8.  i know why i have to use antidepressants 0.42 0.64 0.14 -0.03
 9.  I am using antidepressants, because I was afraid my complaints would come back -0.13 0.27 0.59 0.22
10.  Antidepressants prevent my complaints from coming back 0.47 0.35 0.50 0.09
11.  Using antidepressants resolves your problems 0.28 -0.03 0.70 0.09
12.  The longer you use antidepressants, the better they work 0.18 0.04 0.67 0.05
13.  It took a long time before my antidepressants worked†,* -0.05 0.05 -0.11 -0.05
14.  Owing to antidepressants, i have more energy 0.15 0.21 0.27 0.75
15.  Owing to antidepressants, I sleep better** 0.14 -0.04 -0.06 0.78
16.  Because of antidepressants, I feel physically better 0.33 0.18 0.35 0.57
17.  Because of my antidepressants, I feel mentally better*** 0.51 0.24 0.27 0.44
% of variance explained 34% 9% 7% 6%
Cronbach’s alpha 0.84 0.69 0.62 0.78
Notes: aConvinced of efficacy; beducation about efficacy; cprevention of relapse; dsymptomatic efficacy; *did not load on any of the four factors; **alpha improved after 
deletion of this item; ***thought to reflect the fourth dimension to a greater extent than the first dimension from a theoretical point of view; †reversed scoring, higher score 
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Table S2 items to assess unintentional and intentional nonadherence
Factor loadings of nonadherence items Nonadherence dimensions
Unintentional Intentional
MMAS items
1.  Do you sometimes forget to take your antidepressants? (0, no; 1, yes) excludeda
2.  Over the past 2 weeks, were there any days when you did not take your antidepressants? (0, no; 1, yes) 0.41 0.34
3.  Have you ever cut back or stopped taking your antidepressants without telling your doctor,  
because you felt worse when you took them? (0, no; 1, yes)
-0.07 0.58
4.  When you travel or leave home, do you sometimes forget to bring along your antidepressants? (0, no; 1, yes) 0.58 0.09
5.  Did you take your antidepressants yesterday?† (0, yes; 1, no) 0.16 0.26
6.  When you feel like your symptoms are under control, do you sometimes stop taking your antidepressants?  
(0, no; 1, yes)
0.13 0.61
7.  Taking medication everyday is a real inconvenience for some people. Do you ever feel hassled about  
sticking to your antidepressant­treatment plan? (0, no; 1, yes)
0.43 0.22
8.  How often do you have difficulty remembering to take all your antidepressants?  
(0, never or seldom; 1, once in a while; 2, sometimes; 3 most of the time; 4, always)
0.81 0.00
MARS items (all items: 0, never; 1, seldom; 2, sometimes; 3, often; 4, always)
1.  i forget to use my antidepressants 0.70 0.18
2.  i adjust the dosage of my antidepressants 0.04 0.67
3.  i stop using antidepressants for a while 0.08 0.69
4.  i decide to skip an antidepressant’s dose 0.35 0.43
5.  i take fewer antidepressant tablets than prescribed to me 0.07 0.61
Additional items
1.  i sometimes forgot to take my antidepressants (0, no; 1, yes) 0.87 -0.09
2.  i forgot whether i had already taken my antidepressants (0, no; 1, yes) excludedb
3.  I intend to use antidepressants in the way prescribed (0, fully agree; 4, fully disagree) 0.11 0.50
4.  i intend to discontinue using antidepressants prematurely† (0, fully disagree; 4, fully agree) -0.12 0.40
% of variance explained 23% 16%
Cronbach’s alpha 0.71 0.73
Notes: †reversed scoring, higher score now indicates more nonadherence; aduplicate; bredundant. items were excluded from the total score if they were duplicate items, 
had low or ambiguous factor loadings, or improved Cronbach’s alpha after deletion. The final calculation of the total scores was as follows: intentional nonadherence = 
MMAs i3 + MMAs i5 + MMAs i6 + MArs i2 + MArs i3 + MArs i4 + MArs i5 + additional i3 + additional i4; unintentional nonadherence = MMAs i2 + MMAs i4 + 
MMAs i7 + MMAs i8 + MArs i1 + additional i1.
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